Related Experiment Video
Updated: May 24, 2026
Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
Published on: June 2, 2015
Strategies to defeat ketamine-induced neonatal brain injury
C P Turner1, S Gutierrez, C Liu
1Neurobiology & Anatomy, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1010, USA. cpturner@wfubmc.edu
Insights
General anesthetics like ketamine cause brain cell death in infant rodents. Researchers found that vitamin D3 and an activity-dependent neuroprotective protein (ADNP) peptide fragment could prevent this anesthesia-induced neurotoxicity.
Area of Science:
- Neuroscience
- Developmental Neuroscience
- Pharmacology
Background:
- General anesthetics, such as ketamine, induce apoptosis in the infant rodent brain.
- Clinical studies suggest a link between early-life anesthetic exposure and later learning deficits in children.
- Developing neuroprotective strategies against anesthesia-induced brain injury is crucial.
Purpose of the Study:
- To investigate therapeutic interventions to prevent ketamine-induced neurotoxicity in infant rats.
- To identify potential agents that can mitigate apoptosis in the developing brain following anesthetic exposure.
Main Methods:
- Infant rats (postnatal day 7) were administered ketamine or vehicle.
- Brain tissue was analyzed for activated caspase-3 (AC3) levels via immunohistochemistry.
- Interventions included administration of ADNP peptide fragment (NAPVSIPQ), vitamin D3, or aspirin prior to ketamine exposure.
Main Results:
- Ketamine significantly increased AC3-positive cells, indicating apoptosis.
- Pretreatment with the ADNP peptide fragment NAPVSIPQ dose-dependently reversed ketamine-induced apoptosis.
- Pretreatment with vitamin D3 also prevented ketamine-induced apoptosis.
- Aspirin pretreatment exacerbated AC3 levels in some brain regions.
Conclusions:
- Multiple therapeutic strategies, including ADNP peptide and vitamin D3, can prevent anesthesia-induced neurotoxicity in the infant brain.
- These findings offer alternative approaches for clinicians to manage anesthesia-related risks in pediatric patients.
- Further research into these neuroprotective agents is warranted to enhance therapeutic flexibility.
Abstract:
Studies using animal models have shown that general anesthetics such as ketamine trigger widespread and robust apoptosis in the infant rodent brain. Recent clinical evidence suggests that the use of general anesthetics on young children (at ages equivalent to those used in rodent studies) can promote learning deficits as they mature. Thus, there is a growing need to develop strategies to prevent this injury. In this study, we describe a number of independent approaches to address therapeutic intervention. Postnatal day 7 (P7) rats were injected with vehicle (sterile PBS) or the NMDAR antagonist ketamine (20 mg/kg). After 8 h, we prepared brains for immunohistochemical detection of the pro-apoptotic enzyme activated caspase-3 (AC3). Focusing on the somatosensory cortex, AC3-positive cells were then counted in a non-biased stereological manner. We found AC3 levels were markedly increased in ketamine-treated animals. In one study, microarray analysis of the somatosensory cortex from ketamine-treated P7 pups revealed that expression of activity dependent neuroprotective protein (ADNP) was enhanced. Thus, we injected P7 animals with the ADNP peptide fragment NAPVSIPQ (NAP) 15 min before ketamine administration and found we could dose-dependently reverse the injury. In separate studies, pretreatment of P6 animals with 20 mg/kg vitamin D(3) or a nontoxic dose of ketamine (5 mg/kg) also prevented ketamine-induced apoptosis at P7. In contrast, pretreatment of P7 animals with aspirin (30 mg/kg) 15 min before ketamine administration actually increased AC3 counts in some regions. These data show that a number of unique approaches can be taken to address anesthesia-induced neurotoxicity in the infant brain, thus providing MDs with a variety of alternative strategies that enhance therapeutic flexibility.
